ARMP
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals (ARMP) Q2 2026 earnings
Published Aug 12, 2026
AI summary
- Revenue $2.51M, up 16% from $2.17M a year ago.
- GAAP EPS −$0.27, up from −$0.45 a year ago.
- Armata reported grant and award revenue of $2.5 million for the second quarter of 2026.
- The company recorded a net income of $74.1 million, largely driven by a non-cash gain on a convertible loan.
- Diluted GAAP loss per share was $0.27, compared to a loss of $0.45 in the same quarter last year.
Results vs analyst consensus
Revenue
Reported
$2.51M
Consensus not captured before release
+16% YoY
EPS · GAAP
Reported · GAAP diluted EPS
−$0.27
Consensus not captured before release
Prior year: −$0.45
Consensus: Yahoo Finance · Q2 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company reported a significant non-cash gain from the change in fair value of its convertible loan.
- Operating expenses increased due to higher research and development and administrative costs.
Read original report
Source: Armata Pharmaceuticals, Inc. press release · SEC Form 8-K exhibit 99.1